|Day Low/High||52.45 / 53.62|
|52 Wk Low/High||33.36 / 61.71|
Negative returns for 2022? It's a midterm election year. We will see increased volatility. Anything is possible, and it would not surprise me.
Friday might be a market holiday, but it became obvious on Wednesday that trading volumes had started to truly dwindle.
Mirum Pharmaceuticals and TG Therapeutics are undervalued as stand-alone entities, but also would make easy and logical targets for a larger player.
Perhaps the rally had been set up by the depth of the pressure placed on financial markets over the prior three days. Perhaps.
Bear in mind that as Omicron threatens to, and will to some degree, slow economic activity, the real catalyst will be the political and policy response.
Markets ended mixed for the day as options expire. Pfizer continues to pick up bulls, it seems. Cantor Fitzgerald believes the company's Covid-19 vaccine and hotly anticipated antiviral drug could generate combined peak sales of between $50 billion ...
Market has not moved much since our last update. Biotech continues to be one of the strongest sectors today with the SPDR S&P Biotech ETF up nearly 5% on the day. It will be interesting to see if biotech can hold its gains into the close given it i...
Looks like we are going to open the last day of what has been a miserable week for the markets in the red, based on where futures are currently trading. Small-caps, once again, look like they will take the brunt of the early decline. Skyworks Soluti...
We have new price targets for soaring shares of PFE. Let's check the charts.
Two recent acquisition deals and big drug companies that are flush with cash provide reason to believe biotech stocks could rebound in 2022
The top-10 holdings of Kevin O'Leary's O'Shares FTSE U.S. Quality Dividend ETF are an interesting source of quality dividend growth stocks.
The fact is that some blood hit the floor on Monday.
Yes, volatility beckons. I hear it too. There may be a revaluation of equities across the board in 2022.
Plus, a quick look at earnings report winners and losers from Thursday after the market closed.
I remain more comfortable trading than investing until there is at least one notably upward trading day on notably higher aggregate trading volume.
This quartet has had a rough 2021 but could be in for a rebound next year once investors harvest their losses in the shares.
* The argument for holding above average levels of cash remains intact * I have no interest in chasing the recent market strength * The new regime of volatility in both bonds and stocks may augur poorly for financial asset prices over the next few m...
Plus, One must ask themselves... Are Russia and China satisfied with making Ukraine and Taiwan uncomfortable? Do they understand the costs?
Stick with energy stocks, and realize that in the current no-yield world stocks are bonds.
In the last 30 days, around 95% of stocks are down 25% or more, but the S&P 500 is down only 4%.
Sector selection will remain paramount as pandemic effects continue to permeate.
Satya Nadella's decision to sell almost half his stake in Mr. Softee prompts a closer technical look at what may lie ahead for the tech giant's shares.
* While I am not bullish, I am less bearish * On a (tactical) trading and even on an investing basis, markets may have overreacted to the Omicron news on Friday * I covered a bunch of shorts on Friday * It might be time to consider being a bit more ...
I wouldn't expect a lot in the way of economic shutdowns, at least not unless clear evidence presents that people are getting sicker from Omicron.
PFE has created what appears to potentially be the most effective antiviral for those already infected.